Clinical Trial Update: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) [Phase 2]

View source ↗

Summary

Phase 2 BEAT trial compares atezolizumab alone versus atezolizumab plus bevacizumab as first-line therapy in non-small cell lung cancer; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)
• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Non-small-cell Lung Cancer Patients | Phase 2 | Status: ACTIVE_NOT_RECRUITING